SHSE:603676 (China)
Â
Class A
Â¥
10.32
(+1.57%)
Dec 27
Business Description
Xizang Weixinkang Pharmaceutical Co Ltd
ISIN : CNE100002QQ3
Share Class Description:
SHSE:603676: Class ACompare
Compare
Traded in other countries / regions
603676.China IPO Date
2017-07-21Description
Xizang Weixinkang Pharmaceutical Co Ltd is engaged in research & development, production and sales of chemical pharmaceutical preparations and their raw materials. It also produces and sells liver protection drugs and antibiotic products.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 94.37 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.04 | |||||
| Interest Coverage | 744.83 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 8.25 | |||||
| Beneish M-Score | -3.11 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 21.7 | |||||
| 3-Year EBITDA Growth Rate | 50.1 | |||||
| 3-Year EPS without NRI Growth Rate | 61.6 | |||||
| 3-Year FCF Growth Rate | 28 | |||||
| 3-Year Book Growth Rate | 9.8 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.95 | |||||
| 9-Day RSI | 39.76 | |||||
| 14-Day RSI | 45.81 | |||||
| 6-1 Month Momentum % | 28.41 | |||||
| 12-1 Month Momentum % | 0.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.36 | |||||
| Quick Ratio | 3.27 | |||||
| Cash Ratio | 2.6 | |||||
| Days Inventory | 22.62 | |||||
| Days Sales Outstanding | 59.45 | |||||
| Days Payable | 169.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.33 | |||||
| Dividend Payout Ratio | 0.53 | |||||
| 3-Year Dividend Growth Rate | 73.5 | |||||
| Forward Dividend Yield % | 4.33 | |||||
| 5-Year Yield-on-Cost % | 16.45 | |||||
| 3-Year Average Share Buyback Ratio | -0.9 | |||||
| Shareholder Yield % | 4.24 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 54.49 | |||||
| Operating Margin % | 15.48 | |||||
| Net Margin % | 19.67 | |||||
| FCF Margin % | 25.08 | |||||
| ROE % | 17.63 | |||||
| ROA % | 13.27 | |||||
| ROIC % | 31.26 | |||||
| ROC (Joel Greenblatt) % | 74.72 | |||||
| ROCE % | 18.58 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 18.11 | |||||
| PE Ratio without NRI | 19.15 | |||||
| Shiller PE Ratio | 1.67 | |||||
| Price-to-Owner-Earnings | 23.94 | |||||
| PEG Ratio | 0.66 | |||||
| PS Ratio | 3.66 | |||||
| PB Ratio | 3.03 | |||||
| Price-to-Tangible-Book | 3.14 | |||||
| Price-to-Free-Cash-Flow | 14.5 | |||||
| Price-to-Operating-Cash-Flow | 12.29 | |||||
| EV-to-EBIT | 12.59 | |||||
| EV-to-EBITDA | 12.59 | |||||
| EV-to-Revenue | 2.69 | |||||
| EV-to-FCF | 11.22 | |||||
| Price-to-Projected-FCF | 1.61 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.77 | |||||
| Price-to-Graham-Number | 1.64 | |||||
| Price-to-Net-Current-Asset-Value | 4.91 | |||||
| Price-to-Net-Cash | 7.37 | |||||
| Earnings Yield (Greenblatt) % | 7.94 | |||||
| FCF Yield % | 7.02 | |||||
| Forward Rate of Return (Yacktman) % | 23.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xizang Weixinkang Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,255.829 | ||
| EPS (TTM) (Â¥) | 0.57 | ||
| Beta | 0.56 | ||
| Volatility % | 35.68 | ||
| 14-Day RSI | 45.81 | ||
| 14-Day ATR (Â¥) | 0.331974 | ||
| 20-Day SMA (Â¥) | 10.7165 | ||
| 12-1 Month Momentum % | 0.78 | ||
| 52-Week Range (Â¥) | 6.3 - 11.36 | ||
| Shares Outstanding (Mil) | 435.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xizang Weixinkang Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xizang Weixinkang Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Xizang Weixinkang Pharmaceutical Co Ltd Frequently Asked Questions
What is Xizang Weixinkang Pharmaceutical Co Ltd(SHSE:603676)'s stock price today?
The current price of SHSE:603676 is ¥10.32. The 52 week high of SHSE:603676 is ¥11.36 and 52 week low is ¥6.30.
When is next earnings date of Xizang Weixinkang Pharmaceutical Co Ltd(SHSE:603676)?
The next earnings date of Xizang Weixinkang Pharmaceutical Co Ltd(SHSE:603676) is .
Does Xizang Weixinkang Pharmaceutical Co Ltd(SHSE:603676) pay dividends? If so, how much?
The Dividend Yield %  of Xizang Weixinkang Pharmaceutical Co Ltd(SHSE:603676) is 4.33% (As of Today), Highest Dividend Payout Ratio of Xizang Weixinkang Pharmaceutical Co Ltd(SHSE:603676) was 0.67. The lowest was 0.44. And the median was 0.56. The  Forward Dividend Yield % of Xizang Weixinkang Pharmaceutical Co Ltd(SHSE:603676) is 4.33%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers